#4-21E. Optimizing Second-Line Therapy in RA: Mechanism Switching vs TNFi Cycling (ARD, 2026)

When a rheumatoid arthritis patient fails their first TNF inhibitor, should you cycle to another TNFi or switch mechanisms entirely?, The SELECT-SWITCH trial, a randomized double-blind study, directly addressed this pressing clinical question by comparing upadacitinib, a JAK inhibitor, against adalimumab, a second TNFi, in patients with an inadequate response to a prior non-adalimumab TNFi.,, The study's most crucial finding revealed that switching to the different mechanism of action with upadacitinib yielded significantly superior disease control at 12 weeks, achieving a much higher rate of DAS28-CRP ≤3.2 compared to adalimumab.,, However, when critically appraising this paper, clinicians must note that physical function improvements, measured by the HAQ-DI, did not significantly differ between the groups at this early 12-week endpoint, and patients with severe comorbidities were excluded from the trial, which may limit its real-world generalizability.,, Ultimately, for practicing rheumatologists, these findings provide compelling, head-to-head evidence supporting a shift in treat-to-target strategies; switching the mechanism of action rather than cycling within the TNFi class appears to be the optimal next step to rapidly achieve low disease activity in treatment-resistant patients.

Citation: Mysler E, et al. Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study. Annals of the Rheumatic Diseases. 2026. DOI: 10.1016/j.ard.2026.03.013

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.